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Summary Epidemiological studies showed that bronchial asthma is one of the most
common diseases which can complicate pregnancy (1–7%). In about 0.05–2% of the
cases, asthma occurs as a life-threatening event. In the common medical practice a
waiting strategy or, even, the complete refusal for drug therapies are frequently
observed. This is justified by the fear of the possible adverse effects of drugs on
developing fetus. On the contrary, several studies have demonstrated that severe and
uncontrolled asthma may produce serious maternal and fetal complications, such as
gestational hypertension and eclampsia, fetal hypoxemia and an increased risk of
perinatal death. Therefore, all pregnant women suffering from bronchial asthma
should be considered as potentially at high risk of complications and adequately
treated. Since asthma is a chronic disease with acute exacerbations, a continuous
treatment is mandatory to control symptoms, to prevent acute episodes and to
reduce the degree of airway inflammation. The global strategy for asthma manage-
ment in pregnancy includes five main topics: (1) objective evaluation of maternal/
fetal clinical conditions; (2) avoidance/control of triggering factors; (3) pharmaco-
logical treatment; (4) educational support; (5) psychological support. As far as drug
therapy is concerned, the International Guidelines and Recommendations suggest
that the general strategy does not differ significantly from management outside
pregnancy. We herein review and discuss the available data and the criteria for the
management of asthma in pregnant patients.








The recently published large population-based
epidemiological studies have shown that the pre-
valence of asthma is high and constantly increasing.
This finding is mainly evident in industrialized
countries, but consistent data from developing
and low-income countries are also available.1–3 In
particular, bronchial asthma represents one of
the most frequent diseases that may complicate
pregnancy (about 1–7% of all pregnancies).4,5 In
about 0.05–2% of cases, asthma is a life-threatening
event.6 Unfortunately, it is likely that these figures
may be underestimated, since many patients
suffering from bronchial asthma do not inform
their physicians about the disease.
Uncontrolled asthma can lead to nocturnal
troublesome respiratory symptoms, emergency
department visits, hospitalizations, intubation,
and even death. Similarly, uncontrolled asthma
in pregnancy can have adverse effects on both
the mother and fetus.7,8 In fact, it may result in
serious complications such as fetal hypoxemia and
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reported increased risk of perinatal death,4,9
pregnancy-induced hypertension and preeclamp-
sia,9–11 preterm birth,9,11,12 and low birth
weight.9,11 Furthermore, asthma may worsen ge-
stative hypertension and eclampsia.8,9 However,
Schatz and coworkers,13 who have compared
pregnant patients with actively managed asthma
with healthy control obstetric patients in a pro-
spective case-controlled study, were unable to
document such a finding. They found no difference
in preeclampsia, preterm birth, low birth weight,
IUGR, congenital malformation, and perinatal
mortality.
It must be remarked that the outcome of
pregnancy in optimally treated asthmatic women
does not significantly differ from that of healthy
women.14 Therefore, all pregnant women suffering
from bronchial asthma should be considered as
potentially at high risk of complications15 and
adequately treated. Because prior observations
suggest that severe asthma itself may be associated
with maternal and/or fetal mortality risk, risk/
benefit considerations favor the use of medication,
when indicated, for the treatment of asthma during
pregnancy. However, medical–legal considerations
on the responsibility of physicians and/or specia-
lists (gynaecologist, pulmonologist, etc.) who man-
ages asthma, suggest the need for an adequate
knowledge of the management strategies during
pregnancy, in order to avoid the possibility of
litigation on the respective therapeutic objectives.
Although the presently available experimental data
provide reasonable suggestions and recommenda-
tions, several aspects of the management of
asthma during pregnancy are still a matter of
debate.14
In this review we will outline and discuss the
available data and the criteria for the pharmacolo-
gical management of asthma in pregnant patients.
General aspects of the management
strategy
Bronchial asthma is, in the majority of cases, a
chronic disease sustained by an inflammatory
process. Many triggering factors can intervene at
different levels and time points on the underlying
inflammation (e.g. allergen exposure, emotional
stress, viral infections etc.) thus leading to the
well-known clinical variability of the disease itself.
This means that the onset of asthmatic attacks is
largely unpredictable and it can be controlled only
by a continuous preventive strategy associated to
the control of inflammation. Therefore, the man-
agement strategy is complex and it should be
carried out for long periods.16,17
The objectives of asthma management during
pregnancy are shown in Table 1. The prevention of
asthma exacerbations is essential to avoid recur-
rent episodes of hypoxemia, hypocapnia, alkalosis
and dehydratation. The achievement and mainte-
nance of an optimal respiratory function is manda-
tory to avoid the chronic hypoxemia, which may be
responsible for fetal distress and growth retarda-
tion. Finally, a correct and optimal management,
by avoiding exacerbations, would exclude the need
for acute pharmacological treatments (high do-
sages of drugs) and even for intensive care.
The global strategy of asthma management in
pregnancy includes five essential aspects.18
(1) Objective evaluation of maternal/fetal clinical
conditions.
(2) Avoidance/control of triggering factors.




The management of bronchial asthma during
pregnancy should be carried out by a trained team
of health care professionals such as obstetricians,
midwives, physicians and nurse specialists, plus the
pregnant woman herself, which should manage
together the ongoing problems starting from the
conception until delivery.19,20 A close contact
among different specialists is the ideal way to
optimize asthma management and, in some cases,
to newly diagnose asthma in otherwise unaware
women.18,20
Assessment of the Maternal and Fetal
Status
When evaluating the clinical conditions of a fetus
carried by an woman suffering from moderate to
severe asthma, we should consider it at high risk of
complications.21 Although epidemiological studies
supporting this hypothesis are often not compar-
able each other due to methodological reasons, we
should perform the fetal evaluation keeping into
account these possible complications. An accurate
calculation of the date of onset of pregnancy
represents the first correct approach. In pregnant
patients suffering from bronchial asthma a sono-
graphic evaluation should be performed between
the 16th and 18th weeks, with particular regard to
the location of placenta and the amount of
amniotic fluid.
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In well-controlled asthmatic women with a
regular embryonal growth, usually it is not neces-
sary to perform subsequent unscheduled sono-
graphic assessments. In contrast, in severe or
uncontrolled asthma, the risk of complications is
higher.7,8 Therefore repeated sonographic evalua-
tions should be performed for monitoring fetal
growth. The daily count of fetal movements or
‘‘kicks’’ is a useful marker of fetal vitality.22 In the
case of less than ten movements/hour, other
evaluations, such as external spontaneous monitor-
ing of fetal beats or external monitoring of fetal
beats during spontaneously or induced uterine
contractions are needed.23,24
Every pregnant woman suffering from bronchial
asthma should be evaluated by a detailed clinical
examination and with a routine pulmonary function
test, in order to assess asthma severity. These
clinical and functional evaluations are necessary in
order exclude possible discrepancies between
physician’s and patient’s perception of the disease
and to differentiate asthmatic symptoms from
other causes of dyspnoea during pregnancy.18 A
daily evaluation of peak expiratory flow rate (PEFR)
may also be a useful way to obtain objective
informations about the degree of bronchial ob-
struction throughout the day.
Avoid–Control Triggers for Asthma
Exacerbations
Since bronchial asthma is often associated with
atopy, particularly in young women, an adequate
program of environmental intervention for remov-
ing common indoor allergens such as those pro-
duced by mites, cockroaches and pets must be
always recommended to all pregnant asthmatics25–29
sensitized to those allergens. Despite the results
from meta-analysis of mite-avoidance trials, in-
dicating only a marginal effect on asthma symp-
toms,30 any attempt to reduce environmental
exposure should be made.31 Some essential envir-
onmental care measures are always feasible and
affordable. These include: encasing mattresses and
pillows with impermeable coats, removing carpets
and curtains, vacuum cleaning beds and furniture
with HEPA filters, and hot-washing bed linen and
blankets once a week. Concerning domestic ani-
mals, the only effective measure is to remove the
pet and to carefully vacuuming the environment.
Frequently washing of cats can reduce allergens,
but the overall clinical benefit achieved is mod-
est.32 When they are recognized to be responsible
of symptoms, food additives (such as sulphites),
drugs and ASA should be avoided as well. b-Blockers
are in general contraindicated in asthmatics, but
when they are required for controlling gestational
hypertension, the relative risk/benefit evaluation
should be taken in account.
A particular care should be paid to control
possible viral and bacterial infections, which have
been suggested, to be more frequent in pregnant
than in non-pregnant women.33 For this reason the
contact with people suffering from upper and lower
airways viral and/ or bacterial infections should be
avoided.
General Aspects of Pharmacological
Treatment
In theory, pregnant women should not receive
drugs, especially during the first 3 months of
gestation. In reality, however, asthma in pregnancy
needs to be treated and drugs are necessary, since
uncontrolled asthma represents a risk factor to
both the mother and the fetus.18
The potential teratogenic effects of drugs re-
present the main fear for both physician or patients.
However congenital malformations, including those
that are minor or major, are relatively common
(about 3–5% of all living newborns in the United
States).34 Two to 3% will have a major malforma-
tion, which is defined as one that is incompatible
with survival or one requiring major surgery for
correction or one producing major dysfunction, that
may be confidently attributed, at least in part
(o1%) to drugs administration (teratogenic ef-
fect).34 These malformations may be also induced
by maternal or environmental factors, genetic
factors, although in the majority of the cases the
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Table 1 Goals of asthma management during pregnancy.
Optimal control of respiratory symptoms, including nocturnal exacerbations
Achieving a normal (or close to normal) respiratory function
Allowing to perform usual activities of every day’s life and slight exercise
Avoiding or minimizing asthma exacerbations
Preventing or avoiding side effects due to antiasthma medications for the mother and the fetus
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causes remain unknown. The embryo is most
susceptible during organ formation, from 4 to 10
weeks following the last menstrual period.
Only few drugs really increase teratogenic risk in
humans (Table 2). Nevertheless physicians should
be cautious in prescribing antiasthmatic drugs,
since the possible risks are not completely known.
Consequently, they should provide some simple and
clear information on this topic to their pregnant
patients (Table 3).
Few drugs are reported to be relatively contra-
indicated during lactation (Table 4). In any case,
there are no particular problems for the newborn
by drugs regularly taken by the mother during
pregnancy because the fraction of drugs passing
into breast milk is lower than that passed through
the placenta during gestation.35
The choice of a given drug for treating bronchial
asthma during pregnancy should be carried out
according to some general criteria that are in-
dicated in Table 5.
Unfortunately, the available data on the safety of
antiasthmatic drugs have many limits, mainly due
to the objective (and ethical) problems in assessing
the safety in pregnant women in vivo.36
The US Food and Drug Administration (FDA)
subdivides drugs into five safety categories, based
on the available experimental data. Noteworthy,
none of the drugs usually prescribed for the
treatment of asthma belongs to Pregnancy Risk
Category A, which is characterized by the highest
level of safety (Table 6).37 The other risk categories
report data regarding studies carried out in
experimental animals with few (or any) studies in
humans. Only 0.7% of drugs carry a Pregnancy Risk
Category A classification38 and the vast majority
are in B and C. In particular, 66% of all medications
with a pregnancy category are now in Pregnancy
Risk Category C.39 This classification may not be
considered completely reassuring since the nega-
tive association between drug intake during preg-
nancy and the onset of malformations, per se, did
not guarantee the safety. In fact, no currently
approved asthma medications carry a FDA label of
Pregnancy Risk Category A, which stipulates ‘‘ade-
quate and well controlled studies in pregnant
women have failed to demonstrate a risk to the
fetus in the first trimester of pregnancy and there is
no evidence of risk in later trimester.’’ This
uncertainty reflects the sparsity of data on the
effects of asthma medications during pregnancy.
Recently, some studies have been carried out on
the outcome of a large cohort of pregnancies during
which any drug administration has been carefully
registered. The objectives of these studies were to
evaluate the occurrence, at birth, of ‘‘major
disorders’’ associated with the intake of a given
drug during pregnancy.40,41. In Table 7 are shown
the drugs which did not exhibit a ‘‘strong associa-
tion’’ with the onset of fetal malformations.
Treatment of Chronic Asthma
The recommendations from the National Asthma
Education Program Report of the Working Groups on
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Table 3 Essential informations to be provided to asthmatic pregnant women.
Although only few drugs can be really noxious or harmful during pregnancy, none of the available antiasthmatic
drugs can be considered completely safe, since few controlled studies have been performed in pregnancy
Uncontrolled bronchial asthma have ascertained deleterious effects on the course of pregnancy and represents a
risk factor for the newborn’s health
The risk/benefit ratio in pregnancy of many of antiasthmatic drugs is overall favourable
The choice of the drug(s) to be given is made by the physician according to the clinical situation (severity and
duration of symptoms)








Diuretics can potentially reduce milk production
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Asthma and Pregnancy18 are applicable in most
cases. However, they should be adapted to each
single patient and must be modified when new data
become available in literature.
b2 agonists
Schatz and coworkers42 demonstrated the safety of
inhaled b2-agonist bronchodilators in a prospective
study of 259 pregnant asthmatics who were using b2
agonists compared with 101 pregnant asthmatics
not using bronchodilators and with 295 pregnant
control subjects. Overall, as drug class, the inhaled
b2 agonists are not associated with an increased
frequency of malformation or other unwanted
effects in newborn42. There are no solid data in
literature indicating that one specific b2 agonist
should be considered preferable. Nevertheless,
salbutamol, terbutaline and metaproterenol are
considered short-acting b2 agonists of first choice,
because they have been used for decades without
any reported significant side effect in humans.41,42
The inhalatory route is generally well tolerated and
the use of a spacer can improve the delivery of the
drug to the lungs.43 Oral/parenteral administration
of b2 agonists to asthmatic pregnant women is not
recommended for some important causes, such as
the lack of safety data in the first trimester, the
potential inhibitory effect on the delivery, the
higher rate of side effects (tachycardia and/or
tremors) when comparied with the inhalatory
route.18
The use of short-acting b2 agonists should be
limited when asthma is well controlled. However,
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Table 6 FDA Classification for drugs in pregnancy.
Category Risk based on either animal testing or from
information in humans
Interpretation
A Controlled studies in women fail to
demonstrate a risk to the fetus in the first
trimester, and the possibility of fetal harm
appears remote
This means that there is no evidence of
increased risk in animals or humans
B Animal studies do not indicate a risk to the
fetus, and there are no controlled human
studies. Or animal studies show an adverse
effect on the fetus, but well-controlled
studies in pregnant women have failed to
demonstrate a risk to the fetus
This usually means there is no evidence in
animal studies that risk exists, but no
adequante human data exist
C Studies have shown that the drug exerts
animal teratogenic or embryocidal effects,
but there are no controlled studies in women
or no studies are available in either animals or
women
This usually means there is evidence in animal
studies of a risk of loss of pregnancy or birth
defects, but no adequante human data exist
D Positive evidence of human fetal risk exists,
but benefits in certain situations (for
example, life-threatening situations or serious
diseases for which safer drugs cannot be used
or are ineffective) may make use of the drug
acceptable despite its risks
This means there is evidence of a risk of loss of
pregnancy or birth defects in human
pregnancy that must be balanced against the
value of treatment
X Studies in animals or humans have
demonstrated fetal abnormalities or evidence
of fetal risk, and the risk clearly outweighs
any possible benefit
This means there is evidence of a risk of loss of
pregnancy or birth defects in human
pregnancy without any overriding benefit
Table 5 Criteria for selecting drugs to be administered during pregnancy.
Consult literature databases for potential/described side effects
Give preference to drugs with ascertained efficacy
Give preference to drugs with reassuring human gestational safety data
Use the inhalatory route, when possible
Give preference to drugs available since the most long time period
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when the need for their use increases, inhaled
steroids must start or be increased.18
Only few data are available on the safety during
pregnancy of salmeterol and formoterol, due to
their recent commercial availability. Animal studies
with salmeterol administered parenterally are not
reassuring.44 However the experience with chemi-
cally similar drugs such as salbutamol (animal but
not human studies reporting adverse effects)
suggests that animal studies cannot be entirely
transposed to humans.45 At present, in principle,
the newest agents should not replace salbutamol
and terbutaline, which are proved safe. However, a
post-marketing surveillance study of formoterol in
general practice in England did not show any
important side effect in 33 patients who took
formoterol during pregnancy.46 In any case, it is
important to outline that when asthma symptoms
are not controlled by inhaled corticosteroids, the
addition of salmeterol is more effective than
doubling the dose of steroids.47 Moreover, Pollart
and coworkers48 demonstrated that salmeterol is
more effective and induces fewer side effects than
theophylline. Consequently, long-acting b2 agonists
can be prescribed to pregnant patients, at least
after an in depth evaluation of the risk/benefit
ratio, if they have been successfully treated with
these agents before pregnancy or are suffering
from recurrent nocturnal asthma.
Theophylline
Theophylline carries a Pregnancy Risk Category C.
Although there are no studies on birth defects in
humans, some studies in animals have shown that
theophylline can cause birth defects when given in
doses many times the human dose49. Unfortunately,
the ability to clear theophylline from body may
decrease later in pregnancy;50 therefore dosages of
theophylline may need to be adjusted due to the
changing pharmacokinetics as pregnancy pro-
gresses. Theophylline readily crosses the placenta.
Use of this medicine during pregnancy may cause
unwanted effects, such as fast heartbeat, irrit-
ability, jitteriness, or vomiting, in the newborn
infant if the amount of medicine in mother’s blood
is too high.51 In any case, theophylline may induce
several side effects in pregnancy such as nausea/
gastroesophageal reflux exacerbations, hyperten-
sion, delivery inhibition, etc.
Cromones
Cromolyn sodium is considered safe in pregnancy
because of its virtually complete absence of
systemic side effects.52 Further studies are neces-
sary to confirm the equivalent safety of the newer
cromone sodium nedocromil, although there is no
pharmacological reason to expect a different safety
profile. However, nedocromil has an FDA pregnancy
category B rating, meaning that although human
data are not available, teratogenic events were not
demonstrated in animal studies.
Inhaled corticosteroids (ICS)
ICS are the cornerstones of long-term therapy of
bronchial asthma because they effectively control
inflammation, and reduce asthma exacerbations
and the need for on-demand bronchodilators.53,54
Some controlled studies on the safety profile of
these drugs in pregnancy, which are in any case
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Table 7 Drugs that apparently are not associated with congenital malformations.
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reassuring, are presently available in the litera-
ture.55 Unfortunately, they are few and for this
reason, all inhaled corticosteroids, except budeso-
nide, remain at Pregnancy Risk Category C. The FDA
has upgraded inhaled budesonide to Pregnancy Risk
Category B based on data from three Swedish
registries covering over 2000 births from 1995–1997
(i.e. Swedish Medical Birth Registry; Registry of
Congenital Malformations: Child Cardiology Regis-
try). The studies showed no increased risk of
congenital malformations when pregnant women
used budesonide.56 The new, upgraded rating for
budesonide may make it the drug of choice for
pregnant women who need an inhaled corticoster-
oid to control their asthma. However, despite the
upgraded rating, this drugFlike all drugsFshould
be used during pregnancy only when clearly needed
and when the benefit to the mother outweighs the
risk to the fetus.
Adequate and well-controlled studies regarding
the use of fluticasone during pregnancy have not
been done. Its use during pregnancy should be
avoided unless the potential benefit justifies the
potential but unknown risk to the fetus, also
considering that in animal studies, fluticasone given
by injection was shown to cause birth defects.57
However, considering the route of administration it
is unlikely it can induce serious side effects on
developing fetus. Recently, Ellegard and cowor-
kers58 have evaluated the effect of 8 weeks of
treatment with fluticasone propionate aqueous
nasal spray in 53 women with pregnancy rhinitis.
There was no detectable influence on maternal
cortisol as measured by morning serum-cortisol and
overnight 12-h-urine-cortisol, or any difference in
ultrasound measures of fetal growth or pregnancy
outcome.
Ipratropium bromide
Ipratropium bromide is an anticholinergic agent
which is considered safe and which is largely used
for the treatment of chronic obstructive pulmonary
diseases,44 but no data concerning its use in
pregnancy are available, although studies in rats,
mice and rabbits showed no birth defects when this
medication is used. Since it does not offer
significant advantages over b2 agonists, it cannot
be considered as first choice drugs, and adrenergic
bronchodilators are preferred.
Leukotriene modifiers
Montelukast and zafirlukast are now widely com-
mercialized. Animal studies on zafirlukast and on
montelukast have not detected problems during
pregnancy; however, no human gestational data are
available for any of these drugs.For this reason,
both zafirlukast and montelukast carry FDA Preg-
nancy Risk Category B classification, whereas
zileuton carries Pregnancy Risk Category C classifi-
cation because of adverse effects in animal
studies.59 A Pregnancy Risk Category B or C rating
does not imply that the medication cannot be
prescribed during gestation. The physician is
advised to weigh the benefit to the patient versus
the risks, which, if any exist, are usually not known
at the time.60 Therefore, these drugs should be
used only in pregnant women with resistant asthma
who has previously responded successfully.45
Systemic corticosteroids
Systemic corticosteroids may be needed in preg-
nant women requiring steroid therapy for severe
asthma. In such cases, the lowest effective dosage
must be used, possibly on alternate days. Corticos-
teroid therapy in pregnancy is also appropriate to
treat an in utero infant suffering from neonatal
lupus-associated carditis, in stress doses (in corti-
costeroid-treated patients) for labor and delivery,
and, pre-delivery, to induce fetal lung matura-
tion.61 Chronic use of oral corticosteroids, or even
assumption of high-dose systemic steroid during
pregnancy does carry some risk. Perlow and cow-
orkers reported an increased incidence of diabetes
mellitus, preterm labor, premature rupture of
membranes, preterm delivery, and low-birth-
weight infants in 31 steroid-dependent pregnant
asthmatics.62 An association with preeclampsia has
been noted.63,64 Also an increased incidence of
pregnancy-induced hypertension in pregnant asth-
matic women taking corticosteroids in comparison
to nonsteroid-treated asthmatics has been de-
scribed.5 In animals, systemic corticosteroids have
been associated with cleft palate, placental in-
sufficiency, spontaneous abortion, and growth
retardation.65 In humans, data derived from the
Spanish Collaborative Study of Congenital Malfor-
mations have shown a relationship between ex-
posure to corticosteroids during the first trimester
of pregnancy and an increased risk of cleft lip (with
or without cleft palate) in the newborn infants.66
However, this study suffers from several deficien-
cies.67 First, the histories of first trimester drug
exposures were obtained retrospectively from the
mothers after delivery and diagnosis of the con-
genital abnormality, possibly leading to recall bias.
Second, only four of 1184 infants with oral clefts
had a history of corticosteroid exposure. Third, the
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period of corticosteroid exposure was highly vari-
able, with one exposure of only two doses of 40mg
of prednisolone. Finally, the logistic regression
model in this study did not include confounding
variables of maternal illness or degree of smoking.
Even if this association of corticosteroids and
malformations is confirmed, the incidence of oral
clefts in children of women receiving corticoster-
oids in the first trimester was only 0.4%,66
substantially less than the incidence of untoward
perinatal outcome in poorly controlled asthma.
Two other case–control studies have associated first
trimester maternal use of systemic corticos-
teroids with an increased risk of oral clefts.68,69
However, a population-based case control study of
teratogenic potential of corticosteroids has demon-
strated that there has been no association with
cleft palate or other congenital anomalies.70 Many
normal infants have been born to mothers who have
received systemic corticosteroids throughout
pregnancy, but there have been reports of low
birth-weight71 and an increased risk of hyperbilir-
ubinemia.72
Asthma exacerbations during pregnancy
Pregnancy should be an indication for maximizing
therapy during an asthma exacerbation, rather
than withholding therapy, because neonatal out-
comes are clearly superior when maternal symp-
toms are controlled, and oxygenation and
pulmonary function are optimized.71 Potential
harm to the fetus is more likely to result from
severe uncontrolled asthma rather than from the
medications used to treat it.73 Nevertheless, during
asthma exacerbations, both subjective and objec-
tive parameters must be carefully evaluated. For
instance, hearth rate is usually higher in pregnancy.
If heart rate is higher than 120 beats/min in the
absence of other causes of tachycardia such as
fever, use of b2 agonists, anxiety, anaemia, etc. the
negative prognostic value may be significant. A
similar attention should be devoted to a paradox
pulse >12mmHg.
The peak expiratory flow rate (PEFR) measure-
ment is easy to perform and provides a useful
additional clinical datum. A diurnal variability of
PEFR >30% must be considered as an alert signal,74
as well as the decrease below 92% of the arterial
oxygen saturation (SpO2) as measured by pulse
oximetry.75
Treatment is no different from the emergency
management of acute severe asthma outside
pregnancy. Oxygen, nebulized b2 agonists, nebu-
lised ipratropium, oral or intravenous steroids and,
in severe cases, intravenous aminophylline or
parenteral b2 agonists should be used as indicated.
A suggested protocol for the treatment of asthma
exacerbations, according to the degree of severity
is shown in Fig. 1.
It has been suggested that theophylline added to
adequate b2 agonist and systemic corticosteroid
therapy does not increase benefit for acute asthma
exacerbations, particularly in first four hours of
treatment.18,54
As previously reported, physicians should evalu-
ate the risk/benefit ratio in prescribing systemic
corticosteroids in pregnancy, but they must always
prescribe these agents when they are essential as in
the case of severe acute exacerbations of asthma.
Recently Cydulka and coworkers73 studied the
modality of asthma treatment in pregnant and
non-pregnant women referred to emergency de-
partments. They demonstrated that both groups
received comparable amounts of nebulised b2
agonist treatment in the first hour, but the
pregnant women were significantly less likely to
be given systemic steroids (44% versus 66%). The
pregnant women were equally likely to be admitted
(24% versus 21%), but were less likely to be
prescribed steroids if sent home (38% versus 64%).
At the 2 week follow up interview the pregnant
women were three times more likely to report an
ongoing exacerbation of their asthma.
A number of case reports indicate magnesium is
beneficial for treating acute severe asthma.76 The
suggested mechanism of action is smooth-muscle
relaxation secondary to inhibition of Ca++ influx by
blocking the voltage-dependent calcium chan-
nels.77 Thus, it could be classified as a pure
bronchodilator and theoretically would work best
in situations when airway edema is not the
most prominent feature of status asthmaticus.78
Some reports indicate that it is useful and safe in
the treatment of status asthmaticus even in
pregnancy79.
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Fig. 1 A suggested protocol for the treatment of asthma
exacerbations according to the degree of asthma
severity.
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Asthma During Delivery
Although the risk of asthma exacerbation during
delivery is relatively low, pregnant patient should
not discontinue their inhalation therapy, if any. If
bronchial symptoms are not adequately controlled
by b2 agonists an additional administration of
intravenous methilprednisolone may be necessary.
If a pregnant asthmatic patient has been treated
for long periods with oral steroids, she should
receive parenteral steroids (hydrocortisone 100mg
6–8 h) during labor, and until she is able to restart
her oral medication to prevent the possible onset of
adrenal failure.80
The use of oxytocic drugs such as prostaglandin
(PG)F2a, methilergonovine or ergonovine should be
avoided in asthmatic women during delivery,
because these agents may determine bronchial
obstruction.81 Oxytocine represents a good alter-
native to the use of methilergonovine or ergono-
vine.14 The use of steroids is recommended when
presumably oxytocin is not effective. On the
contrary, high doses of b2 agonists and/or theophyl-
line may determine a retardation of the onset of
delivery.
Oxygen administration may be necessary, after
the evaluation of blood gases, to maintain an
adequate oxemia. When possible, local (peridural)
anesthesia should be preferred to a general
anaesthesia because of the increased risk of chest
infection and associated atelectasis. When a gen-
eral anesthesia is required (caesarean section),
propofol is considered to be the agent of choice for
induction of anesthesia in asthmatics.82 Non-ster-
oidal antiinflammatory drugs (NSAIDs) are com-
monly used for pain relief following a caesarean
section. Women with asthma should be asked about
any known sensitivity to aspirin or NSAIDs before
using these drugs.20
Other Treatments
Specific immunotherapy is generally well tolerated
during pregnancy and its use is not associated with
fetal malformations or complications of pregnancy
and/or of delivery.83 Nevertheless, the risk of
severe or life-threatening reactions must be taken
in account although it seems to be a remote
possibility. It is generally believed that an ongoing
and well-tolerated immunotherapy does not need
to be discontinued during pregnancy. In this
condition, a significant reduction of usual dosage
of allergenic extract may be necessary to avoid the
risk of systemic reactions.84 On the other hand,
based on risk/benefit considerations, it is not
recommended to start a new immunotherapy
course once pregnancy has begun.
The use of epinephrine during pregnancy is
strictly indicated only in the case of anaphy-
laxis85,86 or status asthmaticus because it may
induce a contraction of uterine blood vessels and
consequently a reduction of blood flow.87
H1 receptor blockers are not per se an antiasth-
matic treatment; however they are frequently used
when rhinitis symptoms are present.88,89 Most H1
receptor blockers did not cause birth defects in
animal studies. These include diphenhydramine and
chlorpheniramine, as well as dimenhydrinate dex-
chlorpheniramine, brompheniramine, cetirizine,
loratadine, azatadine, doxylamine, tripelenna-
mine, cyproheptadine, clemastine, and ebastine.
However, animal studies indicated that if taken in
extremely high doses (far above the recommended
dosage), certain antihistamines could cause birth
defects in animal offspring.90 Since data on the
safety of H1 blockers during pregnancy are not
conclusive they should be, in general, avoided,88
although some reassuring human data have been
published for several agents.91,92 For instance, the
use of terfenadine in the first trimester has not
been associated with congenital malformation,
although some data have shown an association
between maternal exposure to terfenadine and a
lower infant birth weight.93 It is important to
outline that few studies addressing small samples
of patients may not exclude the risk of congenital
malformations or other complications. In any case,
the older H1 blockers diphenhydramine and dex-
chlorpheniramine and the newer non-sedating
cetrizine and loratadine carry FDA Pregnancy Risk
Category B classification, whereas hydroxizine,
terfenadine, astemizole, and fexofenadine carry
FDA Pregnancy Risk Category C classification.94
Education and Psychological Aspects
The patients’ education is mandatory to optimize
the outcomes of therapy in asthmatic patients.
However, in the case of pregnant women, strict and
repeated reassurance on the significance and safety
of a regular therapy for controlling airway inflam-
mation is definitely essential to ensure adequate
compliance.20 The physician in charge of asthma
should identify the degree of asthma severity and
the possible triggering factors such as allergens and
pollutants, supply with psychological support and
warrant his/her availability in the case of asthma
exacerbations.
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It seems of primary importance that the patient
can have regular and frequent contacts with
physicians who are in charge of both pregnancy
and asthma. This simple fact may reassure the
patient and reduce her emotional stress. A clear
and simple explanation of the nature of the
disease, its risks and possible treatments should
be able to make the patient more confident
towards medications and diagnostic procedures.
Only in the case of severe mood/behavior distur-
bances, the help of a psychiatric consultant should
be asked.
Conclusions
The problem of asthma management in pregnancy
has received during the last ten years an increasing
attention and, in parallel, our knowledge has
rapidly improved. This improvement is due to
several factors, including: (a) the detailed informa-
tion on the mechanisms underlying bronchial
inflammation; (b) the data provided by large
epidemiological studies; (c) the introduction in
clinical practice of new drugs and their molecular
mechanisms. On the other hand, since pharmaco-
logical studies in pregnant women are usually
unethical and difficult to perform, recommenda-
tions must necessarily be based on the available
clinical experience.95
Several guidelines and recommendations have
been published. They agree on the fact that the
general strategy of management of asthma in
pregnancy does not differ significantly from man-
agement outside pregnancy. The complete control
of symptoms and the prevention of exacerbations
are the primary objectives, since it is ascertained
that poorly controlled asthma is responsible for the
potential small risk of harm to the fetus. These
goals can be reached by using a little number of
drugs which are in use since decades, whereas the
prescription of the newest treatment should be
carefully evaluated case by case.
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